We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Packaging Revives Potential for Highly Toxic Cancer Drug

By LabMedica International staff writers
Posted on 28 Dec 2014
Print article
Image: 3BrPA (red) encased in a sugar-based microshell (Photo courtesy of Dr. Jean-Francois Geschwind, Johns Hopkins University).
Image: 3BrPA (red) encased in a sugar-based microshell (Photo courtesy of Dr. Jean-Francois Geschwind, Johns Hopkins University).
Cancer researchers have shown that sequestering the highly toxic drug 3-bromopyruvate (3BrPA) in a sugar-based molecular microcapsule protects the drug from being inactivated in the bloodstream and eliminates the toxicity that prevents its general use as a chemotherapeutic agent.

Investigators at Johns Hopkins University (Baltimore, MD, USA) encased molecules of 3BrPA in a polymeric coating made from the sugar cyclodextrin. This coating prevented the premature disintegration of the 3BrPA drug molecules and safeguarded healthy tissue from the drug's toxic effects.

Phase-contrast microscopy, bioluminescence imaging (BLI), zymography, and Matrigel assays were used to characterize the effects of the drug in vitro. In vivo effects were studied by using the encapsulated drug to treat a mouse model carrying human pancreatic tumor xenografts.

Results of the Matrigel invasion assay as well as zymography published in the October 17, 2014, online edition of the journal Clinical Cancer Research revealed that the encapsulated drug showed anti-invasive effects in sub-lethal concentrations. In vivo, animals treated with the encapsulated 3BrPA demonstrated minimal or no tumor progression as evident by the BLI signal as opposed to control animals treated with the drug gemcitabine or with only the cyclodextrin. In contrast to animals treated with free 3-BrPA, no lethal toxicity was observed for the encapsulated drug.

“We developed 3BrPA to target a hallmark of cancer cells, namely their increased dependency on glucose compared with normal cells. But the nonencapsulated drug is toxic to healthy tissues and inactivated as it navigates through the blood, so finding a way to encapsulate the drug and protect normal tissues extends its promise in many cancers as it homes in on tumor cells,” said senior author Dr. Jean-Francois Geschwind, professor of radiology at Johns Hopkins University. “The extremely promising results of the study make the encapsulated drug a good candidate for clinical trials, particularly for patients with pancreatic ductal adenocarcinoma.”

Related Links:

Johns Hopkins University


Gold Member
Troponin T QC
Troponin T Quality Control
Unit-Dose Packaging solution
HLX
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test
New
Automated Cell Counter
QuadCount

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.